A research firm projects rapid growth through 2033. Other published estimates put the market on a much smaller scale, making definitions as important as the headline number.
India’s medical tourism industry has a new $53.7 billion forecast. Coherent Market Insights estimates the market at $19.7 billion in 2026 and projects it will reach $53.7 billion by 2033, equivalent to annual compound growth of 15.4%.
The figures appeared in a November 12 company press release distributed by GlobeNewswire. Yahoo Finance’s version labels it a paid press release. These are a commercial researcher’s estimates, not reported national revenue.
CMI points to lower treatment costs, specialist hospitals and overseas referral networks as drivers of demand. Its public announcement also identifies travel disruption and limited cross-border insurance coverage as constraints. The growth case therefore depends on more than adding hospital beds.
Two estimates, very different starting points
A May 2026 backgrounder from India’s Press Information Bureau cites industry estimates of $8.7 billion in 2025 and $16.2 billion by 2030. Even that later figure is below CMI’s estimate for 2026.
The comparison doesn’t establish that either forecast is wrong. It establishes that readers shouldn’t treat them as one continuous data series. The public summaries don’t provide enough comparable methodological detail to reconcile the gap.
Before using a market estimate, a hospital or investor needs to know what it counts. Does the total cover treatment alone, or also accommodation, facilitators and wellness services? Does it count only foreign visitors? Are prices held constant, or does expected price growth help lift the forecast?
Those choices can change the result substantially. A projected dollar total also cannot tell us how many additional patients will receive treatment, or whether their care will improve.

Patient arrivals offer a separate measure
The same government backgrounder reports 507,244 foreign arrivals for medical treatment in 2025. Bangladesh accounted for 325,127, followed by Iraq at 30,989 and Uzbekistan at 13,699.
Bangladesh therefore represented roughly 64% of the reported total, based on those figures. That concentration matters commercially: a national growth plan needs to consider what happens when access from its largest source market becomes harder.
Arrival figures measure a different thing from market value. They don’t reveal the bill for each trip, the number of procedures performed or the outcome of treatment. Dividing one publisher’s revenue estimate by another source’s arrival count would not produce a dependable average patient bill without first checking that both cover the same activity and period.
The costs patients actually need to compare
For someone considering treatment abroad, the relevant figure is the cost of their own care. A useful written quotation should separate the procedure, diagnostics, medicines, rehabilitation and accommodation, and explain charges for an extended stay.
A hospital can make those checks easier by publishing clear package terms and explaining who takes responsibility after discharge. For the industry, evidence of repeat referrals, transparent bills and reliable follow-up would say more about durable growth than a forecast alone. The next useful question is how much of the projected demand becomes care that patients can afford and safely complete.



